Law360, New York (September 15, 2009) -- A federal appeals court refused again Tuesday to overturn an injunction barring Hoffmann-La Roche Inc. from selling its anemia drug Mircera in the U.S., but did partially reinvigorate the Swiss drugmaker's battle with Amgen Inc. by vacating a ruling holding claims of three of Amgen's five disputed anemia drug patents valid.
The U.S. Court of Appeals for the Federal Circuit further vacated a decision that Roche had not infringed one of those disputed claims and remanded that question and the issue...
